<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924937</url>
  </required_header>
  <id_info>
    <org_study_id>CORDIOPREV</org_study_id>
    <nct_id>NCT00924937</nct_id>
  </id_info>
  <brief_title>CORonary Diet Intervention With Olive Oil and Cardiovascular PREVention</brief_title>
  <acronym>CORDIOPREV</acronym>
  <official_title>Randomized Clinical Trial on the Effects of Mediterranean Diet (Rich on Olive Oil) in the Reduction of Coronary Events of Patients With Coronary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Reina Sofia de Cordoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Reina Sofia de Cordoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of the consumption of two different
      dietary patterns (low fat versus Mediterranean Diet) on the incidence of cardiovascular
      events of persons with coronary disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized clinical trial involving 1002 patients with coronary disease that are undergoing
      one of two diets in a randomized design (two groups; Mediterranean Diet 502 patients, Low Fat
      500 patients) for 7 years. The two diets are: a)Low fat diet: &lt;30% fat (12-14%
      monounsaturated fatty acids (MUFA); 6-8% polyunsaturated fatty acid (PUFA) ; &lt;10% SAT) and b)
      Mediterranean Diet: &gt;35% fat (22% MUFA; 6% PUFA ; &lt;10% SAT).

      Primary Objective:

      Combined apparition of hard cardiovascular events (myocardial infarction, revascularization,
      ischemic stroke, documented peripheral artery disease or cardiovascular death).

      Secondary Objectives:

      Those related in the Outcome Measures section of this webpage
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2009</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined apparition of hard cardiovascular events (myocardial infarction, revascularization, ischemic stroke, documented peripheral artery disease or cardiovascular death) after a median follow-up of 7 years.</measure>
    <time_frame>Seven Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of intermittent claudication.</measure>
    <time_frame>Seven Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of LDL cholesterol.</measure>
    <time_frame>Seven Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atherogenic ratio Total cholesterol/HDL and LDL/HDL.</measure>
    <time_frame>Seven Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic control of carbohydrates (assessed by glycemic and insulin responses to intravenous tolerance test to glucose).</measure>
    <time_frame>Seven Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure.</measure>
    <time_frame>Seven Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of malignancy.</measure>
    <time_frame>Seven Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of Cognitive Decline.</measure>
    <time_frame>Seven Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extended composite of cardiovascular disease progression</measure>
    <time_frame>Seven Years</time_frame>
    <description>Incidence of cardiac death, myocardial infarction, angina event, coronary revascularization or cardiac transplant, stroke, symptomatic heart failure, or any other clinical manifestation of cardiovascular event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extended composite of heart events</measure>
    <time_frame>Seven Years</time_frame>
    <description>Cardiac death , myocardial infarction , unstable angina , revascularization, heart failure, heart transplantation, cardiac arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of type 2 Diabetes Mellitus</measure>
    <time_frame>Up to Seven Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Metabolic Syndrome</measure>
    <time_frame>Up to Seven Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of the different families of Gut Microbiota</measure>
    <time_frame>Up to Seven Years</time_frame>
    <description>Changes in the percentage of different families of Microbiota will be analyzed during the study</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Endothelial function (Flow mediated dilation)</measure>
    <time_frame>Up to Seven Years</time_frame>
    <description>Endothelium response to ischemia in the brachial artery. Area under the curve, flow peak and time to maximum flow will be performed</description>
  </other_outcome>
  <other_outcome>
    <measure>genetics</measure>
    <time_frame>Up to seven years</time_frame>
    <description>Influence of genotype in the development of type 2 dm, at 1, 2, 4 and 7 years</description>
  </other_outcome>
  <other_outcome>
    <measure>postprandial lipaemia</measure>
    <time_frame>Up to seven years</time_frame>
    <description>Influence of metabolic phenotypes and diet on postprandial lipemia</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1002</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Unstable Angina</condition>
  <condition>Malignancy</condition>
  <condition>Cognitive Decline</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Low Fat Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Intervention with a Low fat diet: &lt;30% fat (12% monounsaturated fatty acids; 6-8%polyunsaturated fatty acids; &lt;10% saturated fatty acids)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mediterranean Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Intervention with a Mediterranean Diet: 35-38% fat (22% monounsaturated fatty acids; 6% polyunsaturated fatty acids; &lt;10% saturated fatty acids).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mediterranean Diet</intervention_name>
    <description>Mediterranean Diet:35-38% fat (22% MUFA; 6% PUFA; &lt;10% SAT).</description>
    <arm_group_label>Mediterranean Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low Fat Diet</intervention_name>
    <description>Low fat diet: &lt;30% fat (12% MUFA; 6-8%PUFA; &lt;10% SAT)</description>
    <arm_group_label>Low Fat Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent

          -  Clinical: Unstable coronary disease with documented vessel/myocardial damage

               -  Acute Myocardial Infarction

               -  Revascularization

        Exclusion Criteria:

          -  Age &lt; 20 or &gt; 75 years (or life expectancy lower than 5 years).

          -  Patients already planned for revascularization.

          -  Patients submitted to revascularization in the last 6 months

          -  Grade II-IV Heart failure.

          -  Left ventricle dysfunction with ejection fraction lower than 35%.

          -  Patients unable to follow a protocol.

          -  Patients with severe uncontrol of Diabetes Mellitus, or those with Renal Insufficiency
             with plasma creatinine higher than 2mg/dl, or cerebral complications of Diabetes
             mellitus.

          -  Other chronic diseases:

               -  Psychiatric diseases

               -  Renal Insufficiency

               -  Chronic Hepatopathy

               -  Active Malignancy

               -  Chronic obstructive pulmonary disease

               -  Diseases of the digestive tract Endocrine disorders

          -  Patients participating in other Clinical trials (in the enrollment moment or 30 days
             prior).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Perez-Jimenez, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reina Sofia University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reina Sofia University Hospital</name>
      <address>
        <city>Cordoba</city>
        <zip>14001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cordioprev.es/index.php/en/</url>
    <description>Webpage of the study</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2009</study_first_submitted>
  <study_first_submitted_qc>June 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2009</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Reina Sofia de Cordoba</investigator_affiliation>
    <investigator_full_name>Francisco Perez Jimenez</investigator_full_name>
    <investigator_title>Chief of Internal Medicine Unit</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular events</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Incidence of Cancer</keyword>
  <keyword>Cognitive decline</keyword>
  <keyword>Mediterranean Diet</keyword>
  <keyword>Secondary Prevention</keyword>
  <keyword>Low fat diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

